Message #25 From:
Stock News Bot Date: January 18, 2007 06:36:00 AM
NPHC News Designer Diagnostics Announces Positive Results from In-Vitro Analysis
BOCA RATON, Fla.--(BUSINESS WIRE)--Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is
developing drugs for HIV and Multiple Sclerosis, has today announced
that its subsidiary, Designer Diagnostics, has received positive results
from its in-vitro analysis of its Tuberculosis (TB) test kit.
“The results from this study exceeded our
expectations,” explained Neil Roth, President
of Designer Diagnostics, Inc. “We believe that
our test kit will significantly improve speed and accuracy when treating
TB patients worldwide,” he added.
Currently there are over 14.6 million people that have active TB disease
with over one third of the world's population having the TB bacterium in
their bodies with new infections occurring at a rate of one per second.
Normal culturing methods can take as long as 10 weeks to produce
results, where Designer Diagnostics test kits have shown similar results
within 10 days.
“This in-vitro analysis is significant to the
future growth of Designer Diagnostics,”
commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Designer
Diagnostics will now move into human clinical trials, the final step
before bringing this product to market,” he
concluded.
Designer Diagnostics is currently in discussions with the leading
tuberculosis research institutes in the United States to complete human
trials of the test kit technology. The Company expects to complete human
trials and begin shipment within the next 4 to 6 weeks.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the
acquisition, licensing and commercialization of pharmaceutical products
and technologies for the management of neurological disorders, cancer,
autoimmune and infectious diseases. Nutra Pharma Corp. through its
subsidiaries carries out basic drug discovery research and clinical
development and also seeks strategic licensing partnerships to reduce
the risks associated with the drug development process. The Company's
holding, ReceptoPharm, Inc., is developing technologies for the
production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's
subsidiary, Designer Diagnostics, is engaged in the research and
development of diagnostic test kits designed to be used for the rapid
identification of infectious diseases such as Tuberculosis (TB) and
Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to
identify and acquire intellectual property and companies in the
biotechnology arena.
This press release contains forward-looking statements. The words or
phrases "would be," "will allow," "intends to," "will likely result,"
"are expected to," "will continue," "is anticipated," "estimate,"
"project," or similar expressions are intended to identify
"forward-looking statements." Actual results could differ materially
from those projected in Nutra Pharma's ("the Company") business plan.
The Company's business is subject to various risks, which are discussed
in the Company's filings with the Securities and Exchange Commission
("SEC").The results from the Designer Diagnostics
in-vitro analysis should not be construed as an indication in any way
whatsoever of the value of the Company or its common stock.The
Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.Statements made herein are as of the date of this press release and
should not be relied upon as of any subsequent date. The Company
cautions readers not to place reliance on such statements. Unless
otherwise required by applicable law, we do not undertake, and we
specifically disclaim any obligation, to update any forward-looking
statements to reflect occurrences, developments, unanticipated events or
circumstances after the date of such statement.
